Stock CUV CLINUVEL PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Clinuvel Pharmaceuticals Limited

Equities

CUV

AU000000CUV3

Market Closed - Australian S.E.
Other stock markets
 11:40:43 01/05/2024 am IST 		5-day change 1st Jan Change
15.06 AUD +0.07% Intraday chart for Clinuvel Pharmaceuticals Limited +1.14% -5.88%
29/04 Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% MT
14/03 Clinuvel Pharmaceuticals Launches Share Buyback Program MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%
MT
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
AQ
Clinuvel Pharmaceuticals Launches Share Buyback Program
MT
Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16
MT
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.
CI
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.
CI
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
AQ
Clinuvel Reports Positive Results in SCENESSE Study
MT
Transcript : Clinuvel Pharmaceuticals Limited, H1 2024 Earnings Call, Feb 22, 2024
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office
CI
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment
MT
Transcript : Clinuvel Pharmaceuticals Limited - Special Call
Clinuvel Pharmaceuticals Limited Announces Board Changes
CI
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse
MT
Ex-dividend day for final dividend
FA
Transcript : Clinuvel Pharmaceuticals Limited, 2023 Earnings Call, Aug 29, 2023
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023
CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CUV Stock
  4. News Clinuvel Pharmaceuticals Limited